Apollomics (APLM) Non-Current Assets (2021 - 2025)

Apollomics (APLM) posted quarterly Non-Current Assets of $663000.0 for Q4 2025, down 95.86% quarter-over-quarter from $16.0 million in Q2 2023.

Apollomics (APLM) Non-Current Assets (2021 - 2025) Analysis & Trends

Apollomics (APLM) has reported Non-Current Assets for 4 consecutive years, with $663000.0 the latest figure, recorded in Q4 2025.

In Q4 2025, Non-Current Assets changed N/A year-over-year to $663000.0; the TTM figure through Dec 2025 stood at $663000.0 (changed N/A YoY), while the FY2025 annual figure was $663000.0, changed N/A from the prior year.
Non-Current Assets declined to $663000.0 in Q4 2025 per APLM's latest filing, from $16.0 million in the prior quarter.
Across five years, Non-Current Assets topped out at $20.7 million in Q4 2022 and bottomed at -$99.4 million in Q4 2021.
Historically, Non-Current Assets has averaged -$15.5 million across 4 years, with a median of $8.3 million in 2023.
On a YoY basis, Non-Current Assets climbed as much as 120.82% in 2022 and fell as far as 120.82% in 2022.
Apollomics' Non-Current Assets stood at -$99.4 million in 2021, then soared by 120.82% to $20.7 million in 2022, then decreased by 22.63% to $16.0 million in 2023, then sank by 95.86% to $663000.0 in 2025.
Business Quant data shows APLM's Non-Current Assets at $663000.0 in Q4 2025, $16.0 million in Q2 2023, and $20.7 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Assets (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	14.88 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	23.28 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.96 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	5.15 Bn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.96 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	938.60 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	468.65 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	18.06 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	6.80 Bn
10	Apollomics	34.08 Mn	30.81 Mn	-	663,000.00

Download Data